Universe · entity
MPM BioImpact LLC
Institutional manager (13F) · CIK 1687078
13F holdings · as of 2026-03-31 · top 41 · reported portfolio $1.3B
| # | Issuer | Value | Shares |
|---|---|---|---|
| 1 | DBV Technologies S A | $109M | 5,213,361 |
| 2 | Cullinan Therapeutics, Inc. | $109M | 7,648,268 |
| 3 | Aktis Oncology, Inc. | $87M | 4,835,872 |
| 4 | Liquidia Corporation | $53M | 1,405,158 |
| 5 | Alumis Inc | $53M | 2,386,529 |
| 6 | Edgewise Therapeutics Inc | $52M | 1,660,696 |
| 7 | Revolution Medicines, Inc. | $49M | 506,776 |
| 8 | Agios Pharmaceuticals Inc | $44M | 1,306,261 |
| 9 | Corcept Therapeutics, Inc. | $40M | 985,700 |
| 10 | Trevi Therapeutics Inc | $39M | 3,298,430 |
| 11 | Dianthus Therapeutics Inc | $36M | 423,982 |
| 12 | Xenon Pharmaceuticals Inc | $34M | 588,706 |
| 13 | MoonLake Immunotherapeutics | $34M | 1,811,082 |
| 14 | Travere Therapeutics Inc | $34M | 1,133,365 |
| 15 | Evommune Inc | $33M | 1,455,863 |
| 16 | Cytokinetics Inc | $33M | 500,000 |
| 17 | Syndax Pharmaceuticals Inc | $31M | 1,340,733 |
| 18 | Context Therapeutics Inc | $28M | 10,679,391 |
| 19 | Forte Biosciences, Inc. | $26M | 1,000,682 |
| 20 | Palvella Therapeutics Inc | $26M | 206,404 |
| 21 | Dyne Therapeutics, Inc. | $26M | 1,408,152 |
| 22 | Stoke Therapeutics Inc | $25M | 767,038 |
| 23 | Corvus Pharmaceuticals Inc | $25M | 1,674,875 |
| 24 | Relay Therapeutics Inc. | $23M | 2,359,586 |
| 25 | Tarsus Pharmaceuticals Inc | $23M | 329,750 |
| 26 | Oric Pharmaceuticals Inc | $23M | 1,803,945 |
| 27 | Uniqure NV | $22M | 1,369,231 |
| 28 | Monte Rosa Therapeutics Inc | $19M | 1,176,928 |
| 29 | Natera Inc | $19M | 93,074 |
| 30 | Climb Bio Inc | $18M | 2,593,439 |
| 31 | Arcutis Biotherapeutics Inc | $17M | 733,966 |
| 32 | Urogen Pharma Ltd | $17M | 943,803 |
| 33 | Bright Minds Biosciences Inc | $15M | 212,175 |
| 34 | Zymeworks, Inc. | $14M | 565,249 |
| 35 | Belite Bio Inc | $14M | 88,045 |
| 36 | Viridian Therapeutics Inc | $13M | 649,873 |
| 37 | enGene Holdings, Inc. | $13M | 1,845,373 |
| 38 | Abivax SA | $12M | 107,268 |
| 39 | Allogene Therapeutics, Inc. | $5M | 2,242,933 |
| 40 | Aclaris Therapeutics Inc | $1M | 391,918 |
| 41 | Werewolf Therapeutics, Inc. | $1M | 1,208,810 |
Source: sec_edgar_13f · public regulatory · retrieved 2026-06-29. Public SEC data; no contact information.